August 2nd, 2021

A full text version of this article is available.
To access article obtain online access here or login
Anti-Müllerian Hormone Cannot Predict Oocyte Quality and Pregnancy Outcome in Women with Diminished Ovarian Reserve
Authors:  Xiruo Zhang, M.D., Xuan Gao, M.D., Linlin Cui, M.D., Ph.D, Bowen Ma, B.S., Yingying Qin, M.D., Ph.D., and Zi-Jiang Chen, M.D., Ph.D.
  OBJECTIVE: To compare anti-Müllerian hormone (AMH) levels in serum and follicular fluid (FF) among women <40 yrs with diminished ovarian reserve (DOR), advanced age (AA) women (>40 yrs), and age-matched women (<40 yrs) with normal ovarian reserve (NOR) and to explore the relationship of AMH with oocyte quality and pregnancy outcome.

STUDY DESIGN: Serum and FF AMH levels and oocyte quality, clinical pregnancy rate (CPR), and live birth rate (LBR) were analyzed in 149 women.

RESULTS: Both serum and FF AMH concentrations were significantly lower in DOR and AA as compared with those in NOR (median serum AMH: 0.33 ng/mL vs. 0.51 ng/mL vs. 2.35 ng/mL; median FF AMH: 2.32 ng/mL vs. 2.66 ng/mL vs. 6.77 ng/mL, p<0.01). The rate of good-quality embryos on D2 was comparable among the 3 groups. A 2-fold higher CPR was found in NOR than DOR (62.79% vs. 38.3%, p<0.01), along with a remarkably higher LBR (60.47% vs. 31.91%, p<0.01). The lowest CPR and LBR were observed in AA (17.5%; 5.00%). No association of either serum or FF AMH with CPR, LBR, and the rate of good-quality embryos on D2 was indicated.

CONCLUSION: AMH can-not predict either oocyte quality or pregnancy outcome in a DOR population. A better pregnancy outcome could be anticipated in younger women with DOR as compared with AA women.
Keywords:  anti-mullerian hormone, assisted reproductive technologies, follicular fluid, in vitro fertilization, oocyte quality, ovarian reserve, pregnancy outcome, serum
  Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from